Cue Biopharma licenses Ascendant-221 anti-IgE antibody from Ascendant Health Sciences

Cue Biopharma, Inc.

Cue Biopharma, Inc.

CUE

0.00
  • Cue Biopharma entered an exclusive license deal with Ascendant Health Sciences to develop, manufacture, commercialize Ascendant-221, a Phase 2 anti-IgE antibody for allergic diseases.
  • Cue received global rights excluding mainland China, Hong Kong, Macau, Taiwan.
  • Agreement includes USD 15 million upfront payment.
  • Ascendant eligible for up to USD 676.5 million in development, regulatory, commercial milestones.
  • Cue targets global Phase 2b food allergy trial following Phase 2 chronic spontaneous urticaria readout expected in 2H 2026 from Ascendant Health-led China study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.